BIOMAT Database Logo BIOMAT Database Logo

New bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation. 2021

Mohammed M Alanazi, and Hazem A Mahdy, and Nawaf A Alsaif, and Ahmad J Obaidullah, and Hamad M Alkahtani, and Abdulrahman A Al-Mehizia, and Sultan M Alsubaie, and Mohammed A Dahab, and Ibrahim H Eissa
Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh, Saudi Arabia. Electronic address: mmalanazi@KSU.EDU.SA.

A new series of bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives were designed and synthesized to have the main essential pharmacophoric features of VEGFR-2 inhibitors. VEGFR-2 inhibitory activities were assessed for the designed compounds. In addition, cytotoxic activity was evaluated for all derivatives against two human cancer cell lines namely, HepG-2 and MCF-7. The most cytotoxic compound 20 h was subjected to further biological investigations including cell cycle, apoptosis, caspase-3, caspase-9, BAX, and Bcl-2 analyses. Different in silico studies as docking, ADMET and toxicity were carried out. The results exhibited that compounds 20b, 20e, 20h and20mshowed promising VEGFR-2 inhibitory activities with IC50values of 5.7, 6.7, 3.2, and 3.1 µM, respectively. Moreover, these promising members exhibited the highest antiproliferative activities against the two cell lines with IC50values ranging from 3.3 to 14.2 µM, comparing to sorafenib (IC50 = 2.17 and 3.43 µM against HepG2 and MCF-7, respectively). Additionally, compound 20h induced cell cycle arrest of HepG2 cells at G2/M phase. Also, such compound increased the progress of apoptosis by 3.5-fold compared to the control. As well, compound 20h showed a significant increase in the level of caspase-3 (2.07-fold), caspase-9 (1.72-fold), and BAX (1.83-fold), and a significant decrease in Bcl-2 level (1.92-fold). The in silico studies revealed that the synthesized compounds have binding pattern like that of sorafenib.

UI MeSH Term Description Entries
D011810 Quinoxalines Quinoxaline
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014230 Triazoles Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3. Triazole
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis

Related Publications

Mohammed M Alanazi, and Hazem A Mahdy, and Nawaf A Alsaif, and Ahmad J Obaidullah, and Hamad M Alkahtani, and Abdulrahman A Al-Mehizia, and Sultan M Alsubaie, and Mohammed A Dahab, and Ibrahim H Eissa
Discovery of new VEGFR-2 inhibitors based on bis([1, 2, 4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as anticancer agents and apoptosis inducers.
December 2021, Journal of enzyme inhibition and medicinal chemistry,
Mohammed M Alanazi, and Hazem A Mahdy, and Nawaf A Alsaif, and Ahmad J Obaidullah, and Hamad M Alkahtani, and Abdulrahman A Al-Mehizia, and Sultan M Alsubaie, and Mohammed A Dahab, and Ibrahim H Eissa
Benzoxazole derivatives as new VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, in silico studies, and antiproliferative evaluation.
December 2022, Journal of enzyme inhibition and medicinal chemistry,
Mohammed M Alanazi, and Hazem A Mahdy, and Nawaf A Alsaif, and Ahmad J Obaidullah, and Hamad M Alkahtani, and Abdulrahman A Al-Mehizia, and Sultan M Alsubaie, and Mohammed A Dahab, and Ibrahim H Eissa
Design, Synthesis, and Biological Evaluation of [1,2,4]triazolo[4,3-a] Pyrazine Derivatives as Novel Dual c-Met/VEGFR-2 Inhibitors.
January 2022, Frontiers in chemistry,
Mohammed M Alanazi, and Hazem A Mahdy, and Nawaf A Alsaif, and Ahmad J Obaidullah, and Hamad M Alkahtani, and Abdulrahman A Al-Mehizia, and Sultan M Alsubaie, and Mohammed A Dahab, and Ibrahim H Eissa
Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers.
December 2021, Journal of enzyme inhibition and medicinal chemistry,
Mohammed M Alanazi, and Hazem A Mahdy, and Nawaf A Alsaif, and Ahmad J Obaidullah, and Hamad M Alkahtani, and Abdulrahman A Al-Mehizia, and Sultan M Alsubaie, and Mohammed A Dahab, and Ibrahim H Eissa
New [1,2,4]triazolo[4,3-c]quinazoline derivatives as vascular endothelial growth factor receptor-2 inhibitors and apoptosis inducers: Design, synthesis, docking, and antiproliferative evaluation.
October 2022, Archiv der Pharmazie,
Mohammed M Alanazi, and Hazem A Mahdy, and Nawaf A Alsaif, and Ahmad J Obaidullah, and Hamad M Alkahtani, and Abdulrahman A Al-Mehizia, and Sultan M Alsubaie, and Mohammed A Dahab, and Ibrahim H Eissa
[1,2,4]Triazolo[4,3-c]quinazoline and bis([1,2,4]triazolo)[4,3-a:4',3'-c]quinazoline derived DNA intercalators: Design, synthesis, in silico ADMET profile, molecular docking and anti-proliferative evaluation studies.
January 2021, Bioorganic & medicinal chemistry,
Mohammed M Alanazi, and Hazem A Mahdy, and Nawaf A Alsaif, and Ahmad J Obaidullah, and Hamad M Alkahtani, and Abdulrahman A Al-Mehizia, and Sultan M Alsubaie, and Mohammed A Dahab, and Ibrahim H Eissa
New [1,2,4]triazolo[4,3-c]quinazolines as intercalative Topo II inhibitors: Design, synthesis, biological evaluation, and in silico studies.
January 2023, PloS one,
Mohammed M Alanazi, and Hazem A Mahdy, and Nawaf A Alsaif, and Ahmad J Obaidullah, and Hamad M Alkahtani, and Abdulrahman A Al-Mehizia, and Sultan M Alsubaie, and Mohammed A Dahab, and Ibrahim H Eissa
New benzoxazole derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, anti-proliferative evaluation, flowcytometric analysis, and in silico studies.
December 2022, Journal of enzyme inhibition and medicinal chemistry,
Mohammed M Alanazi, and Hazem A Mahdy, and Nawaf A Alsaif, and Ahmad J Obaidullah, and Hamad M Alkahtani, and Abdulrahman A Al-Mehizia, and Sultan M Alsubaie, and Mohammed A Dahab, and Ibrahim H Eissa
Design, synthesis, and molecular docking studies of new [1,2,4]triazolo[4,3-a]quinoxaline derivatives as potential A2B receptor antagonists.
February 2021, Molecular diversity,
Mohammed M Alanazi, and Hazem A Mahdy, and Nawaf A Alsaif, and Ahmad J Obaidullah, and Hamad M Alkahtani, and Abdulrahman A Al-Mehizia, and Sultan M Alsubaie, and Mohammed A Dahab, and Ibrahim H Eissa
Design, synthesis, anticancer evaluation, and molecular modelling studies of novel tolmetin derivatives as potential VEGFR-2 inhibitors and apoptosis inducers.
December 2021, Journal of enzyme inhibition and medicinal chemistry,
Copied contents to your clipboard!